NIH grant fuels research to find improved treatments for heart failure, aiming to advance care and enhance outcomes for ...

Alnylam Pharmaceuticals Inc. (ALNY) said that new data from the HELIOS-B Phase 3 study of vutrisiran showed that the drug attenuated ...

Capricor announced it intends to file a BLA for deramiocel for treatment of patients with DMD cardiomyopathy. Click here to ...

Edgewise Therapeutics (NASDAQ: EWTX) is up 50% in a single session and 450% from recent lows for a reason. Its novel, oral, ...

It affects about 1 in 2,000 to 1 in 5,000 people, most of whom are between 20 and 40 years old.With ARVC, scar and fatty ...

Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on Capricor Therapeutics (CAPR – Research Report). The ...

Phoenix researcher was recently awarded a $1.9 million National Institutes of Health grant to study the molecular mechanisms of how dilated cardiomyopathy progresses to heart failure, which could ...

With the recipient facing extreme breathing difficulty, a heart transplant was the only option left. While his family waited ...

Shares of biopharma outfit Edgewise Therapeutics ( EWTX -4.14%) soared more than 50% today, reaching a three-year high ...

Discover BridgeBio Pharma's groundbreaking patent for treating ATTR cardiomyopathy with Compound 1, showcasing improved patient outcomes and reduced mortality rates.

Rocket Pharmaceuticals announced enrollment completion for phase 2 study using its gene therapy RP-A501 for treatment of male ...

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable ...